TMCnet News
Alcobra to Host Investor Forum and Webcast on March 28 in New York CityTEL AVIV, Israel, March 01, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that it will host an investor forum on Tuesday, March 28, 2017 from 8:00-9:30 a.m. EST in New York City. The forum will feature several experts in the field of prescription medication abuse and the treatment and management of attention deficit and hyperactivity disorder (ADHD). In addition, Alcobra’s executive management team will provide an evidence-based overview of the commercial potential for its proprietary Abuse-Deterrent, Amphetamine Immediate Release product candidate called ADAIR. At the forum, Dr. Timothy Wilens and Dr. Stephen Faraone will provide a general overview and answer questions regarding prescription medication abuse and the treatment and management of ADHD. Timothy Wilens, M.D. is chief, Division of Child and Adolescent Psychiatry and co-director Center for Addiction Medicine at Massachusetts General Hospital (MGH). He is also associate professor of psychiatry at Harvard Medical School in Boston. His residency in child, adolescent, adult, and addiction psychiatry was completed at MGH under the auspices of Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit and hyperactivity disorder (ADHD), bipolar disorder and substance use disorders, and the pharmacotherapy of ADHD across the lifespan. Stephen Faraone, Ph.D., vice president of he World Federation of ADHD, studies the nature and causes of mental disorders in childhood. In 2014, 2015 and 2016 Thompson Reuters named Dr. Faraone one of the world’s most highly cited scholars in the fields of psychiatry and psychology. He is an author on over 800 journal articles, editorials, chapters and books, his research interests include genetics, biomarker development, psychopharmacology and research methodology. Dr. Faraone is editor for the journal Neuropsychiatric Genetics and also deputy editor for the Journal of the American Academy of Child and Adolescent Psychiatry. The event will be webcast live beginning at 8:00 a.m. EST. The webcast and accompanying presentation materials will be accessible live and archived on the Investor Relations section of Alcobra’s website at www.alcobra-pharma.com, the content of which is not incorporated herein by reference. To attend the event in person, please contact the company at [email protected]. About ADAIR About Alcobra Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected] |